What We're Reading: Page 385
Industry reads hand-picked by our editors
Feb 09, 2015
Feb 06, 2015
-
Reuters
Merck's hep C treatment loses FDA breakthrough status
-
-
-
Promising Roche Parkinson's med causes lung toxicity in monkey trials
-
-
-
U.S. Chamber knocks IP laggards India, Indonesia, Thailand and Vietnam in Asia
-
Pfizer on fire with early FDA nod for blockbuster Ibrance, $15B Hospira buyout
-
Study: Drug makers fail to meet adverse-event reporting requirements
-
Trans-Pacific Partnership trade talks fail to resolve patent & IP issues
Feb 05, 2015
-
UPDATE: Why Gilead's shares are tumbling despite stellar Q4 earnings
-
Earnings roundup: Merck tops expectations, steady GSK rises on ViiV IPO talk
-
-
US to launch large-scale universal flu shot testing in 2016
-
-
-
-
Moody's: Patent-cliff challenges will continue to dog big pharma
-
Merck's Belsomra for insomnia now available in US
-
Another FDA warning letter for India-based Apotex
Feb 04, 2015
-
UPDATE: Obama budget proposes historic, direct Medicare drug price negotiations
-
-
FTC: Ranbaxy must sell acne drug to Torrent Pharma before Sun takeover
-
-
Sanofi finally launches Afrezza inhaled insulin in the US
-
-
Chimerix shifts from Ebola focus to adenoviruses, CMV as outbreak wanes
-
Ireland threatens to cap drug prices
-
-
FDA approves new Zohydro ER pankiller formulation
Feb 03, 2015
Feb 02, 2015
-
Obama to unveil $215M personalized medicine, million-person DNA sequencing project
-
-
Study: Parkinson's patients' response doubles with 'expensive' placebo
-
-
-
-
-
Biogen Idec re-enters gene therapy R&D with hemophilia focus
-
J&J under continued scrutiny for off-label pediatric use of Risperdal
-
Some UK cystic fibrosis patients being denied breakthough treatment
Jan 30, 2015
-
-
Largest US health insurer latest to give Harvoni preferred hep C drug status
-
-
Study: Parkinson's patients' response doubles with 'expensive' placebo
-
-
Pfizer dodges class-action trial with $400 million settlement
-
-
-
Express Scripts claims it's saved US healthcare $4B through hep C deals
-
Earnings update: Roche plateaus, Amgen stock slides despite solid performance
Previous
